Experienced drug developer, most recently at Almirall, to lead Bioniz’s clinical trials of novel, selective…
Read More
IRVINE, Calif., January 4, 2020 – Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company advancing…
- BNZ-1 showed an overall response rate (ORR) of 63.2% based on the Global Response…
As a multi-cytokine inhibitor, BNZ-1 is a novel immuno-oncology drug that integrates inhibition of malignant…
Irvine, California July, 2020– Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing first-in-class peptide…
Irvine, CA, January, 2020 – Bioniz Therapeutics, Inc., a privately held clinical stage biopharmaceutical company…
Irvine, CA, April 4, 2018 — Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing…
Thomas P. Loughran, Jr., MD, is the director of the UVA Cancer Center, F. Palmer…
— First Data from BNZ-1 Phase 1 trial to be Highlighted in Oral Presentation- Irvine,…
— Company’s product candidate BNZ-2, potentially constitutes a unique therapeutic approach for patients with Celiac…
